Σιπροφλοξασίνη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Σιπροφλοξασίνη" in Greek language version.

refsWebsite

Global rank Greek rank

59nih.gov

4^th place

39doi.org

2^nd place

3^rd place

17web.archive.org

1^st place

12fda.gov

447^th place

368^th place

11archive.org

6^th place

5^th place

3books.google.com

3^rd place

6^th place

3google.com

163^rd place

168^th place

2drugs.com

399^th place

130^th place

2clincalc.com

3,912^th place

594^th place

2cdc.gov

218^th place

156^th place

1webmd.com

1,169^th place

603^rd place

1jfponline.com

low place

1tga.gov.au

3,984^th place

2,133^rd place

1aafp.org

1,916^th place

1,112^th place

1uroweb.org

low place

1worldcat.org

5^th place

8^th place

1scot.nhs.uk

low place

1uptodate.com

3,771^st place

3,079^th place

1state.mn.us

3,210^th place

7,063^rd place

1toku-e.com

low place

9,912^th place

1masson.fr

low place

1sec.gov

572^nd place

763^rd place

aafp.org

«Quinolones: a comprehensive review». American Family Physician 65 (3): 455–64. February 2002. PMID 11858629. http://www.aafp.org/link_out?pmid=11858629.

archive.org

«Fluoroquinolone prescribing in the United States: 1995 to 2002». The American Journal of Medicine 118 (3): 259–68. March 2005. doi:10.1016/j.amjmed.2004.09.015. PMID 15745724. https://archive.org/details/sim_american-journal-of-medicine_2005-03_118_3/page/259.
«Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection». Antimicrobial Agents and Chemotherapy 57 (5): 2326–32. May 2013. doi:10.1128/AAC.02176-12. PMID 23478961. PMC 3632900. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_2013-05_57_5/page/2326.
«Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials». Mayo Clinic Proceedings 81 (12): 1553–66. December 2006. doi:10.4065/81.12.1553. PMID 17165634. https://archive.org/details/sim_mayo-clinic-proceedings_2006-12_81_12/page/1553.
«Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials». Family Practice 29 (6): 659–70. December 2012. doi:10.1093/fampra/cms029. PMID 22516128. https://archive.org/details/sim_family-practice_2012-12_29_6/page/659.
«Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study». Antimicrobial Agents and Chemotherapy 42 (6): 1336–9. June 1998. doi:10.1128/AAC.42.6.1336. PMID 9624471. PMC 105599. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1998-06_42_6/page/1336.
«Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women». Antimicrobial Agents and Chemotherapy 37 (2): 293–6. February 1993. doi:10.1128/AAC.37.2.293. PMID 8452360. PMC 187655. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1993-02_37_2/page/293.
Royal Pharmaceutical Society of Great Britain (2009). «5 Infections». British National Formulary (BNF 57). BMJ Group and RPS Publishing. ISBN 978-0-85369-845-6.
First aid for the USMLE step 2 CK (6th έκδοση). McGraw-Hill Medical. Ιουνίου 2007. ISBN 9780071487955.
«DNA gyrase, topoisomerase IV, and the 4-quinolones». Microbiology and Molecular Biology Reviews 61 (3): 377–92. September 1997. doi:10.1128/.61.3.377-392.1997. PMID 9293187. PMC 232616. https://archive.org/details/sim_microbiology-and-molecular-biology-reviews_1997-09_61_3/page/377.
«Urinary tract antiseptics». The Medical Clinics of North America 66 (1): 199–208. January 1982. doi:10.1016/s0025-7125(16)31453-5. PMID 7038329. https://archive.org/details/sim_medical-clinics-of-north-america_1982-01_66_1/page/199.
«Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates». Antimicrobial Agents and Chemotherapy 21 (5): 848–51. May 1982. doi:10.1128/AAC.21.5.848. PMID 6213200. PMC 182027. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1982-05_21_5/page/848.

books.google.com

Oxford Handbook of Infectious Diseases and Microbiology. OUP Oxford. 2009. σελ. 56. ISBN 978-0-19-103962-1.
Fischer, Jnos· Ganellin, C. Robin (2006). Analogue-based Drug Discovery (στα Αγγλικά). John Wiley & Sons. σελ. 500. ISBN 9783527607495.
Hamilton, Richard J. (2014). Tarascon pharmacopoeia (15 έκδοση). Jones & Bartlett Publishers. σελ. 85. ISBN 978-1-284-05671-6.

cdc.gov

Department of Health and Human Services· Centers for Disease Control and Prevention (Νοεμβρίου 2004). «Gonococcal Isolate Surveillance Project (GISP) Annual Report - 2003» (PDF). USA: Center for Disease Controlo. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 24 Απριλίου 2009. Ανακτήθηκε στις 31 Αυγούστου 2009.
Centers for Disease Control Prevention (CDC) (April 2007). «Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections». MMWR. Morbidity and Mortality Weekly Report 56 (14): 332–6. PMID 17431378. Αρχειοθετήθηκε από το πρωτότυπο στις 8 December 2016. https://web.archive.org/web/20161208045713/http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm.

clincalc.com

«The Top 300 of 2020». ClinCalc. Ανακτήθηκε στις 11 Απριλίου 2020.
«Ciprofloxacin - Drug Usage Statistics». ClinCalc. Ανακτήθηκε στις 11 Απριλίου 2020.

doi.org

dx.doi.org

«A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections». Treatments in Respiratory Medicine 5 (6): 437–65. 2006. doi:10.2165/00151829-200605060-00009. PMID 17154673.
«Quinolone generations: natural history or natural selection?». The Journal of Antimicrobial Chemotherapy 46 Suppl T1: 17–24. July 2000. doi:10.1093/oxfordjournals.jac.a020889. PMID 10997595.
«Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America». Clinical Infectious Diseases 50 (2): 133–64. January 2010. doi:10.1086/649554. PMID 20034345.
«Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America». Circulation 111 (23): e394–434. June 2005. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145.
«Practice guidelines for the diagnosis and management of skin and soft-tissue infections». Clinical Infectious Diseases 41 (10): 1373–406. November 2005. doi:10.1086/497143. PMID 16231249.
«Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America». Clinical Infectious Diseases 56 (1): e1–e25. January 2013. doi:10.1093/cid/cis803. PMID 23223583.
«International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases». Clinical Infectious Diseases 52 (5): e103–20. March 2011. doi:10.1093/cid/ciq257. PMID 21292654.
«Ciprofloxacin in acute exacerbations of chronic bronchitis». The Journal of Antimicrobial Chemotherapy 18 (3): 407–13. September 1986. doi:10.1093/jac/18.3.407. PMID 3490468.
«Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials». CMAJ 179 (12): 1269–77. December 2008. doi:10.1503/cmaj.080358. PMID 19047608.
«Ciprofloxacin in general practice». BMJ 308 (6941): 1437. May 1994. doi:10.1136/bmj.308.6941.1437. PMID 8019264.
«Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials». CMAJ 178 (7): 845–54. March 2008. doi:10.1503/cmaj.071157. PMID 18362380.
«IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults». Clinical Infectious Diseases 54 (8): e72–e112. April 2012. doi:10.1093/cid/cir1043. PMID 22438350.
«Systemic use of fluoroquinolone in children». Korean Journal of Pediatrics 56 (5): 196–201. May 2013. doi:10.3345/kjp.2013.56.5.196. PMID 23741232.
«Bacterial resistance to ciprofloxacin in Greece: results from the National Electronic Surveillance System. Greek Network for the Surveillance of Antimicrobial Resistance». Emerging Infectious Diseases 5 (3): 471–6. 1999. doi:10.3201/eid0503.990325. PMID 10341191.
«Fluoroquinolone prescribing in the United States: 1995 to 2002». The American Journal of Medicine 118 (3): 259–68. March 2005. doi:10.1016/j.amjmed.2004.09.015. PMID 15745724. https://archive.org/details/sim_american-journal-of-medicine_2005-03_118_3/page/259.
«Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis». Medicine (Baltimore) 96 (44): e8273. November 2017. doi:10.1097/MD.0000000000008273. PMID 29095256.
«Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection». Antimicrobial Agents and Chemotherapy 57 (5): 2326–32. May 2013. doi:10.1128/AAC.02176-12. PMID 23478961. PMC 3632900. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_2013-05_57_5/page/2326.
«Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials». Mayo Clinic Proceedings 81 (12): 1553–66. December 2006. doi:10.4065/81.12.1553. PMID 17165634. https://archive.org/details/sim_mayo-clinic-proceedings_2006-12_81_12/page/1553.
«Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials». Family Practice 29 (6): 659–70. December 2012. doi:10.1093/fampra/cms029. PMID 22516128. https://archive.org/details/sim_family-practice_2012-12_29_6/page/659.
«Tendon Injury and Fluoroquinolone Use: A Systematic Review». Drug Saf 36 (9): 709–21. September 2013. doi:10.1007/s40264-013-0089-8. PMID 23888427.
«Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study». Drug Safety 29 (10): 889–96. 2006. doi:10.2165/00002018-200629100-00006. PMID 16970512.
«Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis». Drug Saf 42 (4): 529–538. October 2018. doi:10.1007/s40264-018-0751-2. PMID 30368737.
«Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence». Current Medical Research and Opinion 24 (2): 329–33. February 2008. doi:10.1185/030079908X253735. PMID 18067688.
«Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study». American Journal of Health-System Pharmacy 71 (1): 37–43. January 2014. doi:10.2146/ajhp130165. PMID 24352180.
«Pregnancy Outcomes Following Exposure to Quinolone Antibiotics - a Systematic-Review and Meta-Analysis». Pharm. Res. 35 (5): 109. March 2018. doi:10.1007/s11095-018-2383-8. PMID 29582196.
«Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study». Antimicrobial Agents and Chemotherapy 42 (6): 1336–9. June 1998. doi:10.1128/AAC.42.6.1336. PMID 9624471. PMC 105599. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1998-06_42_6/page/1336.
«Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)». European Journal of Obstetrics, Gynecology, and Reproductive Biology 69 (2): 83–9. November 1996. doi:10.1016/0301-2115(95)02524-3. PMID 8902438.
«Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats». Comparative Biochemistry and Physiology. Toxicology & Pharmacology 136 (1): 95–102. September 2003. doi:10.1016/j.cca.2003.08.004. PMID 14522602.
«Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women». Antimicrobial Agents and Chemotherapy 37 (2): 293–6. February 1993. doi:10.1128/AAC.37.2.293. PMID 8452360. PMC 187655. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1993-02_37_2/page/293.
«New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety». Clinical Infectious Diseases 17 Suppl 1: S192–9. August 1993. doi:10.1093/clinids/17.supplement_1.s192. PMID 8399914.
«Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams». Pharmaceutics 3 (4): 865–913. November 2011. doi:10.3390/pharmaceutics3040865. PMID 24309312.
«Drug interactions with quinolones». The Journal of Antimicrobial Chemotherapy 26 Suppl D: 7–29. November 1990. doi:10.1093/jac/26.suppl_D.7. PMID 2286594.
«Adverse reactions to fluoroquinolones. an overview on mechanistic aspects». Current Medicinal Chemistry 8 (4): 371–84. March 2001. doi:10.2174/0929867013373435. PMID 11172695.
«Drug interactions with quinolone antibacterials». Drug Safety 7 (4): 268–81. 1992. doi:10.2165/00002018-199207040-00003. PMID 1524699.
«The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions». Supportive Care in Cancer 15 (3): 251–7. March 2007. doi:10.1007/s00520-006-0127-5. PMID 17139496.
«DNA gyrase, topoisomerase IV, and the 4-quinolones». Microbiology and Molecular Biology Reviews 61 (3): 377–92. September 1997. doi:10.1128/.61.3.377-392.1997. PMID 9293187. PMC 232616. https://archive.org/details/sim_microbiology-and-molecular-biology-reviews_1997-09_61_3/page/377.
«DNA topoisomerases and their poisoning by anticancer and antibacterial drugs». Chemistry & Biology 17 (5): 421–33. May 2010. doi:10.1016/j.chembiol.2010.04.012. PMID 20534341.
«Urinary tract antiseptics». The Medical Clinics of North America 66 (1): 199–208. January 1982. doi:10.1016/s0025-7125(16)31453-5. PMID 7038329. https://archive.org/details/sim_medical-clinics-of-north-america_1982-01_66_1/page/199.
«Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates». Antimicrobial Agents and Chemotherapy 21 (5): 848–51. May 1982. doi:10.1128/AAC.21.5.848. PMID 6213200. PMC 182027. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1982-05_21_5/page/848.

drugs.com

«Ciprofloxacin Use During Pregnancy». Drugs.com. 7 Ιανουαρίου 2019. Ανακτήθηκε στις 19 Δεκεμβρίου 2019.
«Ciprofloxacin Hydrochloride». The American Society of Health-System Pharmacists. Αρχειοθετήθηκε από το πρωτότυπο στις 23 Σεπτεμβρίου 2015. Ανακτήθηκε στις 23 Αυγούστου 2015.

fda.gov

accessdata.fda.gov

Dianne Murphy (30 Αυγούστου 2000). «Cipro Labeling Revision Letter 08/30/2000 Supplement 008 New or Modified Indication» (PDF). U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 18 Οκτωβρίου 2012.
Renata Albrecht (25 Μαρτίου 2004). «Cipro Labeling Revision Letter 03/25/2004 Supplement 049 Patient Population Altered» (PDF). U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 18 Οκτωβρίου 2012. Ανακτήθηκε στις 7 Σεπτεμβρίου 2009.
«US Cipro label» (PDF). U.S. Food and Drug Administration (FDA). Ιουλίου 2017. For label updates see FDA Index page for NDA 019537
«Cipro IV Meta-analysis» (PDF). U.S. Food and Drug Administration (FDA). Νοεμβρίου 2011.
«CIPRO (ciprofloxacin hydrochloride) TABLETS» (PDF). U.S. Food and Drug Administration (FDA). Ανακτήθηκε στις 13 Οκτωβρίου 2018.
«Cipro Labeling Revision 02/25/2011 Supplement 075» (PDF). U.S. Food and Drug Administration (FDA). 25 Φεβρουαρίου 2011. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 17 Οκτωβρίου 2012. Ανακτήθηκε στις 1 Απριλίου 2011.
«Cipro Labeling Revision 04/06/2009 Supplement 073» (PDF). U.S. Food and Drug Administration (FDA). 6 Απριλίου 2009. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 5 Ιουλίου 2010. Ανακτήθηκε στις 8 Σεπτεμβρίου 2009.
«Cipro Labeling Revision 10/03/2008 Supplement 068» (PDF). U.S. Food and Drug Administration (FDA). 3 Οκτωβρίου 2008. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 14 Δεκεμβρίου 2010. Ανακτήθηκε στις 31 Αυγούστου 2009.
«Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations N019537». U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Ιανουαρίου 2014. Ανακτήθηκε στις 5 Ιανουαρίου 2014.
«Orange Book Detail Record Search». U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Ιανουαρίου 2014.

fda.gov

«Drug Safety and Availability - FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects». U.S. Food and Drug Administration (FDA). Ανακτήθηκε στις 10 Ιανουαρίου 2018.
«Drug Safety and Availability - FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients». U.S. Food and Drug Administration (FDA). Ανακτήθηκε στις 4 Ιανουαρίου 2019.

google.com

jfponline.com

«The perils of prescribing fluoroquinolones». The Journal of Family Practice 62 (4): 191–7. April 2013. PMID 23570031. Αρχειοθετήθηκε από το πρωτότυπο στις 2021-08-28. https://web.archive.org/web/20210828035924/https://www.mdedge.com/familymedicine/article/65086/perils-prescribing-fluoroquinolones. Ανακτήθηκε στις 2020-09-27. Σφάλμα αναφοράς: Μη έγκυρη ετικέτα <ref> • όνομα " He2013 " ορίζεται πολλές φορές με διαφορετικό περιεχόμενο

masson.fr

«[Rupture of the patellar ligament one month after treatment with fluoroquinolone [Rupture of the patellar ligament one month after treatment with fluoroquinolone]»] (στα French). Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur 86 (5): 495–7. September 2000. PMID 10970974. http://www.masson.fr/masson/MDOI-RCO-09-2000-86-5-0035-1040-101019-ART7.

nih.gov

ncbi.nlm.nih.gov

«A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections». Treatments in Respiratory Medicine 5 (6): 437–65. 2006. doi:10.2165/00151829-200605060-00009. PMID 17154673.
«The perils of prescribing fluoroquinolones». The Journal of Family Practice 62 (4): 191–7. April 2013. PMID 23570031. Αρχειοθετήθηκε από το πρωτότυπο στις 2021-08-28. https://web.archive.org/web/20210828035924/https://www.mdedge.com/familymedicine/article/65086/perils-prescribing-fluoroquinolones. Ανακτήθηκε στις 2020-09-27. Σφάλμα αναφοράς: Μη έγκυρη ετικέτα <ref> • όνομα " He2013 " ορίζεται πολλές φορές με διαφορετικό περιεχόμενο
«Quinolone generations: natural history or natural selection?». The Journal of Antimicrobial Chemotherapy 46 Suppl T1: 17–24. July 2000. doi:10.1093/oxfordjournals.jac.a020889. PMID 10997595.
«Quinolones: a comprehensive review». American Family Physician 65 (3): 455–64. February 2002. PMID 11858629. http://www.aafp.org/link_out?pmid=11858629.
«Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America». Clinical Infectious Diseases 50 (2): 133–64. January 2010. doi:10.1086/649554. PMID 20034345.
«Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America». Circulation 111 (23): e394–434. June 2005. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145.
«Practice guidelines for the diagnosis and management of skin and soft-tissue infections». Clinical Infectious Diseases 41 (10): 1373–406. November 2005. doi:10.1086/497143. PMID 16231249.
«Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America». Clinical Infectious Diseases 56 (1): e1–e25. January 2013. doi:10.1093/cid/cis803. PMID 23223583.
«International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases». Clinical Infectious Diseases 52 (5): e103–20. March 2011. doi:10.1093/cid/ciq257. PMID 21292654.
«Ciprofloxacin in acute exacerbations of chronic bronchitis». The Journal of Antimicrobial Chemotherapy 18 (3): 407–13. September 1986. doi:10.1093/jac/18.3.407. PMID 3490468.
«Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials». CMAJ 179 (12): 1269–77. December 2008. doi:10.1503/cmaj.080358. PMID 19047608.
«Ciprofloxacin in general practice». BMJ 308 (6941): 1437. May 1994. doi:10.1136/bmj.308.6941.1437. PMID 8019264.
«Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials». CMAJ 178 (7): 845–54. March 2008. doi:10.1503/cmaj.071157. PMID 18362380.
«IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults». Clinical Infectious Diseases 54 (8): e72–e112. April 2012. doi:10.1093/cid/cir1043. PMID 22438350.
Centers for Disease Control Prevention (CDC) (April 2007). «Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections». MMWR. Morbidity and Mortality Weekly Report 56 (14): 332–6. PMID 17431378. Αρχειοθετήθηκε από το πρωτότυπο στις 8 December 2016. https://web.archive.org/web/20161208045713/http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm.
«Systemic use of fluoroquinolone in children». Korean Journal of Pediatrics 56 (5): 196–201. May 2013. doi:10.3345/kjp.2013.56.5.196. PMID 23741232.
«Bacterial resistance to ciprofloxacin in Greece: results from the National Electronic Surveillance System. Greek Network for the Surveillance of Antimicrobial Resistance». Emerging Infectious Diseases 5 (3): 471–6. 1999. doi:10.3201/eid0503.990325. PMID 10341191.
«Fluoroquinolone prescribing in the United States: 1995 to 2002». The American Journal of Medicine 118 (3): 259–68. March 2005. doi:10.1016/j.amjmed.2004.09.015. PMID 15745724. https://archive.org/details/sim_american-journal-of-medicine_2005-03_118_3/page/259.
«Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis». Medicine (Baltimore) 96 (44): e8273. November 2017. doi:10.1097/MD.0000000000008273. PMID 29095256.
«Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection». Antimicrobial Agents and Chemotherapy 57 (5): 2326–32. May 2013. doi:10.1128/AAC.02176-12. PMID 23478961. PMC 3632900. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_2013-05_57_5/page/2326.
«Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: a meta-analysis of randomized controlled trials». Mayo Clinic Proceedings 81 (12): 1553–66. December 2006. doi:10.4065/81.12.1553. PMID 17165634. https://archive.org/details/sim_mayo-clinic-proceedings_2006-12_81_12/page/1553.
«Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials». Family Practice 29 (6): 659–70. December 2012. doi:10.1093/fampra/cms029. PMID 22516128. https://archive.org/details/sim_family-practice_2012-12_29_6/page/659.
«Tendon Injury and Fluoroquinolone Use: A Systematic Review». Drug Saf 36 (9): 709–21. September 2013. doi:10.1007/s40264-013-0089-8. PMID 23888427.
«[Rupture of the patellar ligament one month after treatment with fluoroquinolone [Rupture of the patellar ligament one month after treatment with fluoroquinolone]»] (στα French). Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur 86 (5): 495–7. September 2000. PMID 10970974. http://www.masson.fr/masson/MDOI-RCO-09-2000-86-5-0035-1040-101019-ART7.
«Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study». Drug Safety 29 (10): 889–96. 2006. doi:10.2165/00002018-200629100-00006. PMID 16970512.
«Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis». Drug Saf 42 (4): 529–538. October 2018. doi:10.1007/s40264-018-0751-2. PMID 30368737.
«Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence». Current Medical Research and Opinion 24 (2): 329–33. February 2008. doi:10.1185/030079908X253735. PMID 18067688.
«Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study». American Journal of Health-System Pharmacy 71 (1): 37–43. January 2014. doi:10.2146/ajhp130165. PMID 24352180.
«[Illness, anxiety and the physician. An example from neurology and neurorehabilitation»]. Wiener Medizinische Wochenschrift 141 (22): 512–25. May 1995. PMID 1801454.
«Pregnancy Outcomes Following Exposure to Quinolone Antibiotics - a Systematic-Review and Meta-Analysis». Pharm. Res. 35 (5): 109. March 2018. doi:10.1007/s11095-018-2383-8. PMID 29582196.
«Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study». Antimicrobial Agents and Chemotherapy 42 (6): 1336–9. June 1998. doi:10.1128/AAC.42.6.1336. PMID 9624471. PMC 105599. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1998-06_42_6/page/1336.
«Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)». European Journal of Obstetrics, Gynecology, and Reproductive Biology 69 (2): 83–9. November 1996. doi:10.1016/0301-2115(95)02524-3. PMID 8902438.
«Fetal and maternal tissue distribution of the new fluoroquinolone DW-116 in pregnant rats». Comparative Biochemistry and Physiology. Toxicology & Pharmacology 136 (1): 95–102. September 2003. doi:10.1016/j.cca.2003.08.004. PMID 14522602.
«Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women». Antimicrobial Agents and Chemotherapy 37 (2): 293–6. February 1993. doi:10.1128/AAC.37.2.293. PMID 8452360. PMC 187655. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1993-02_37_2/page/293.
«New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety». Clinical Infectious Diseases 17 Suppl 1: S192–9. August 1993. doi:10.1093/clinids/17.supplement_1.s192. PMID 8399914.
«Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams». Pharmaceutics 3 (4): 865–913. November 2011. doi:10.3390/pharmaceutics3040865. PMID 24309312.
«Drug interactions with quinolones». The Journal of Antimicrobial Chemotherapy 26 Suppl D: 7–29. November 1990. doi:10.1093/jac/26.suppl_D.7. PMID 2286594.
«Adverse reactions to fluoroquinolones. an overview on mechanistic aspects». Current Medicinal Chemistry 8 (4): 371–84. March 2001. doi:10.2174/0929867013373435. PMID 11172695.
«Drug interactions with quinolone antibacterials». Drug Safety 7 (4): 268–81. 1992. doi:10.2165/00002018-199207040-00003. PMID 1524699.
«Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers». Pakistan Journal of Pharmaceutical Sciences 24 (1): 63–8. January 2011. PMID 21190921.
«Risk of seizures from concomitant use of ciprofloxacin and phenytoin in patients with epilepsy». CMAJ 158 (1): 104–5, 108–9. January 1998. PMID 9475922.
«The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions». Supportive Care in Cancer 15 (3): 251–7. March 2007. doi:10.1007/s00520-006-0127-5. PMID 17139496.
«DNA gyrase, topoisomerase IV, and the 4-quinolones». Microbiology and Molecular Biology Reviews 61 (3): 377–92. September 1997. doi:10.1128/.61.3.377-392.1997. PMID 9293187. PMC 232616. https://archive.org/details/sim_microbiology-and-molecular-biology-reviews_1997-09_61_3/page/377.
«DNA topoisomerases and their poisoning by anticancer and antibacterial drugs». Chemistry & Biology 17 (5): 421–33. May 2010. doi:10.1016/j.chembiol.2010.04.012. PMID 20534341.
«Urinary tract antiseptics». The Medical Clinics of North America 66 (1): 199–208. January 1982. doi:10.1016/s0025-7125(16)31453-5. PMID 7038329. https://archive.org/details/sim_medical-clinics-of-north-america_1982-01_66_1/page/199.
«Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates». Antimicrobial Agents and Chemotherapy 21 (5): 848–51. May 1982. doi:10.1128/AAC.21.5.848. PMID 6213200. PMC 182027. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1982-05_21_5/page/848.

pubmedcentral.nih.gov

«Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials». CMAJ 179 (12): 1269–77. December 2008. doi:10.1503/cmaj.080358. PMID 19047608.
«Ciprofloxacin in general practice». BMJ 308 (6941): 1437. May 1994. doi:10.1136/bmj.308.6941.1437. PMID 8019264.
«Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials». CMAJ 178 (7): 845–54. March 2008. doi:10.1503/cmaj.071157. PMID 18362380.
«Systemic use of fluoroquinolone in children». Korean Journal of Pediatrics 56 (5): 196–201. May 2013. doi:10.3345/kjp.2013.56.5.196. PMID 23741232.
«Bacterial resistance to ciprofloxacin in Greece: results from the National Electronic Surveillance System. Greek Network for the Surveillance of Antimicrobial Resistance». Emerging Infectious Diseases 5 (3): 471–6. 1999. doi:10.3201/eid0503.990325. PMID 10341191.
«Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis». Medicine (Baltimore) 96 (44): e8273. November 2017. doi:10.1097/MD.0000000000008273. PMID 29095256.
«Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection». Antimicrobial Agents and Chemotherapy 57 (5): 2326–32. May 2013. doi:10.1128/AAC.02176-12. PMID 23478961. PMC 3632900. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_2013-05_57_5/page/2326.
«[Illness, anxiety and the physician. An example from neurology and neurorehabilitation»]. Wiener Medizinische Wochenschrift 141 (22): 512–25. May 1995. PMID 1801454.
«Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study». Antimicrobial Agents and Chemotherapy 42 (6): 1336–9. June 1998. doi:10.1128/AAC.42.6.1336. PMID 9624471. PMC 105599. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1998-06_42_6/page/1336.
«Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women». Antimicrobial Agents and Chemotherapy 37 (2): 293–6. February 1993. doi:10.1128/AAC.37.2.293. PMID 8452360. PMC 187655. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1993-02_37_2/page/293.
«Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams». Pharmaceutics 3 (4): 865–913. November 2011. doi:10.3390/pharmaceutics3040865. PMID 24309312.
«DNA gyrase, topoisomerase IV, and the 4-quinolones». Microbiology and Molecular Biology Reviews 61 (3): 377–92. September 1997. doi:10.1128/.61.3.377-392.1997. PMID 9293187. PMC 232616. https://archive.org/details/sim_microbiology-and-molecular-biology-reviews_1997-09_61_3/page/377.
«Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates». Antimicrobial Agents and Chemotherapy 21 (5): 848–51. May 1982. doi:10.1128/AAC.21.5.848. PMID 6213200. PMC 182027. https://archive.org/details/sim_antimicrobial-agents-and-chemotherapy_1982-05_21_5/page/848.

scot.nhs.uk

documents.hps.scot.nhs.uk

Young, Hugh; Palmer, Helen; Winter, Andrew (22 July 2003). «Ciprofloxacin resistant gonorrhoea: the situation in Scotland and implications for therapy». SCIEH Weekly Report 37. ISSN 1357-4493. Αρχειοθετήθηκε από το πρωτότυπο στις 22 July 2011. https://web.archive.org/web/20110722204213/http://www.documents.hps.scot.nhs.uk/ewr/pdf2003/0329.pdf. Ανακτήθηκε στις 30 August 2009.

sec.gov

«www.sec.gov». Αρχειοθετήθηκε από το πρωτότυπο στις 9 Ιουλίου 2017.

state.mn.us

health.state.mn.us

«Bacterial resistance prompts concern among health officials». Minnesota Department of Health. 26 Φεβρουαρίου 2009. Αρχειοθετήθηκε από το πρωτότυπο στις 5 Μαρτίου 2009.

tga.gov.au

«Prescribing medicines in pregnancy database». Australian Government. 23 Αυγούστου 2015. Αρχειοθετήθηκε από το πρωτότυπο στις 8 Απριλίου 2014.

toku-e.com

«Ciprofloxacin Data Sheet» (PDF). Toku-E. 1 Δεκεμβρίου 2010. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 9 Οκτωβρίου 2013. Ανακτήθηκε στις 20 Ιουνίου 2012.

uptodate.com

Hooper, David (12 Φεβρουαρίου 2018). «Fluoroquinolones - UpToDate». UpToDate. Ανακτήθηκε στις 26 Φεβρουαρίου 2018.

uroweb.org

«Guidelines on Urological Infections» (PDF). European Association of Urology. 2013. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 31 Δεκεμβρίου 2013.

web.archive.org

«Ciprofloxacin Hydrochloride». The American Society of Health-System Pharmacists. Αρχειοθετήθηκε από το πρωτότυπο στις 23 Σεπτεμβρίου 2015. Ανακτήθηκε στις 23 Αυγούστου 2015.
«The perils of prescribing fluoroquinolones». The Journal of Family Practice 62 (4): 191–7. April 2013. PMID 23570031. Αρχειοθετήθηκε από το πρωτότυπο στις 2021-08-28. https://web.archive.org/web/20210828035924/https://www.mdedge.com/familymedicine/article/65086/perils-prescribing-fluoroquinolones. Ανακτήθηκε στις 2020-09-27. Σφάλμα αναφοράς: Μη έγκυρη ετικέτα <ref> • όνομα " He2013 " ορίζεται πολλές φορές με διαφορετικό περιεχόμενο
«Prescribing medicines in pregnancy database». Australian Government. 23 Αυγούστου 2015. Αρχειοθετήθηκε από το πρωτότυπο στις 8 Απριλίου 2014.
«Guidelines on Urological Infections» (PDF). European Association of Urology. 2013. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 31 Δεκεμβρίου 2013.
Department of Health and Human Services· Centers for Disease Control and Prevention (Νοεμβρίου 2004). «Gonococcal Isolate Surveillance Project (GISP) Annual Report - 2003» (PDF). USA: Center for Disease Controlo. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 24 Απριλίου 2009. Ανακτήθηκε στις 31 Αυγούστου 2009.
Young, Hugh; Palmer, Helen; Winter, Andrew (22 July 2003). «Ciprofloxacin resistant gonorrhoea: the situation in Scotland and implications for therapy». SCIEH Weekly Report 37. ISSN 1357-4493. Αρχειοθετήθηκε από το πρωτότυπο στις 22 July 2011. https://web.archive.org/web/20110722204213/http://www.documents.hps.scot.nhs.uk/ewr/pdf2003/0329.pdf. Ανακτήθηκε στις 30 August 2009.
Centers for Disease Control Prevention (CDC) (April 2007). «Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections». MMWR. Morbidity and Mortality Weekly Report 56 (14): 332–6. PMID 17431378. Αρχειοθετήθηκε από το πρωτότυπο στις 8 December 2016. https://web.archive.org/web/20161208045713/http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm.
Dianne Murphy (30 Αυγούστου 2000). «Cipro Labeling Revision Letter 08/30/2000 Supplement 008 New or Modified Indication» (PDF). U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 18 Οκτωβρίου 2012.
Renata Albrecht (25 Μαρτίου 2004). «Cipro Labeling Revision Letter 03/25/2004 Supplement 049 Patient Population Altered» (PDF). U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 18 Οκτωβρίου 2012. Ανακτήθηκε στις 7 Σεπτεμβρίου 2009.
«Bacterial resistance prompts concern among health officials». Minnesota Department of Health. 26 Φεβρουαρίου 2009. Αρχειοθετήθηκε από το πρωτότυπο στις 5 Μαρτίου 2009.
«Ciprofloxacin Data Sheet» (PDF). Toku-E. 1 Δεκεμβρίου 2010. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 9 Οκτωβρίου 2013. Ανακτήθηκε στις 20 Ιουνίου 2012.
«Cipro Labeling Revision 02/25/2011 Supplement 075» (PDF). U.S. Food and Drug Administration (FDA). 25 Φεβρουαρίου 2011. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 17 Οκτωβρίου 2012. Ανακτήθηκε στις 1 Απριλίου 2011.
«Cipro Labeling Revision 04/06/2009 Supplement 073» (PDF). U.S. Food and Drug Administration (FDA). 6 Απριλίου 2009. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 5 Ιουλίου 2010. Ανακτήθηκε στις 8 Σεπτεμβρίου 2009.
«Cipro Labeling Revision 10/03/2008 Supplement 068» (PDF). U.S. Food and Drug Administration (FDA). 3 Οκτωβρίου 2008. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 14 Δεκεμβρίου 2010. Ανακτήθηκε στις 31 Αυγούστου 2009.
«Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations N019537». U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Ιανουαρίου 2014. Ανακτήθηκε στις 5 Ιανουαρίου 2014.
«Orange Book Detail Record Search». U.S. Food and Drug Administration (FDA). Αρχειοθετήθηκε από το πρωτότυπο στις 6 Ιανουαρίου 2014.
«www.sec.gov». Αρχειοθετήθηκε από το πρωτότυπο στις 9 Ιουλίου 2017.

webmd.com

«Ciprofloxacin Hcl Drops». WebMD. 22 Φεβρουαρίου 2018. Ανακτήθηκε στις 22 Φεβρουαρίου 2018.

worldcat.org

Young, Hugh; Palmer, Helen; Winter, Andrew (22 July 2003). «Ciprofloxacin resistant gonorrhoea: the situation in Scotland and implications for therapy». SCIEH Weekly Report 37. ISSN 1357-4493. Αρχειοθετήθηκε από το πρωτότυπο στις 22 July 2011. https://web.archive.org/web/20110722204213/http://www.documents.hps.scot.nhs.uk/ewr/pdf2003/0329.pdf. Ανακτήθηκε στις 30 August 2009.